BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 32071051)

  • 1.
    Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
    J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Stone GG; Newell P; Bradford PA
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
    Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
    Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
    Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
    Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
    Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG; Bradford PA; Yates K; Newell P
    J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
    Sader HS; Huband MD; Duncan LR; Flamm RK
    Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012-2016.
    Ramalheira E; Stone GG
    J Glob Antimicrob Resist; 2019 Dec; 19():106-115. PubMed ID: 31295583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
    Stone GG; Bradford PA; Newell P; Wardman A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
    Stone GG; Seifert H; Nord CE
    Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.